Clinical Trials

Phase 1 Active not recruiting

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

316 enrolled

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06963216 2026-02-27

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 3 Recruiting

15 enrolled

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Phase 1/2 Terminated

103 enrolled 21 charts

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT03582033 2024-12-24

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Phase 1 Terminated

83 enrolled 57 charts

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT02978235 2024-09-05

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Phase 1 Terminated

11 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT01183949 2024-08-02

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase 1/2 Completed

18 enrolled

Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Phase 1 Recruiting

81 enrolled

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00457782 2024-04-25

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

27 enrolled

Bronchiolitis Obliterans Syndrome, Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, B-Cell, Lymphoma, B-Cell

NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Completed

95 enrolled 13 charts

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase 1 Unknown

29 enrolled

Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasm, Residual, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Phase 3 Completed

1,718 enrolled 22 charts

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

26 enrolled

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Phase 1 Withdrawn

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Phase 3 Withdrawn

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT00079716 2014-12-18

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

44 enrolled

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

36 enrolled

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT01435720 2014-09-11

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Phase 1/2 Unknown

15 enrolled

Blood Protein Disorders, Hematologic Diseases, Leukemia, Plasma Cell, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT00725634 2014-01-27

P05538

41 enrolled

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

NCT00113204 2008-05-20

IPi-504-01